Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
DUBLIN, Ireland and TREVOSE, Pa., Feb. 18, 2016 -- Strongbridge Biopharma plc (NASDAQ:SBBP) today announced that management will be attending SunTrust Robinson Humphrey’s 2016 Orphan Drug Day on February 23, 2016 in New York City.
About Strongbridge Biopharma
Strongbridge Biopharma's strategic focus is to build a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases. Strongbridge Biopharma's lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor that is currently being studied in the global Phase 3 trial for the treatment of endogenous Cushing's syndrome. Strongbridge Biopharma recently expanded its rare endocrine disease franchise with the completion of transactions for two Phase 2 product candidates: COR-004, a novel second-generation antisense compound, which is in clinical development for the treatment of acromegaly and designed to block the synthesis of growth hormone receptor (GHr), thereby reducing levels of insulin-like growth factor-1 (IGF-1) in the blood; and COR-005, a next-generation somatostatin analog (SSA) with a unique receptor affinity profile, being investigated for the treatment of acromegaly, with potential additional applications in Cushing's disease and neuroendocrine tumors. COR-003 and COR-005 have received orphan designation from both the European Medicines Agency and the U.S. Food and Drug Administration, and the Company is pursuing orphan designation for COR-004. Strongbridge Biopharma's intent is to independently commercialize its rare endocrine assets in key global markets.
Contacts: Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304 [email protected] Investor Relations ICR Inc. Stephanie Carrington +1 646-277-1282 [email protected] USA 900 Northbrook Drive Suite 200 Trevose, PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389
